Evidence map›Paper›PMID 33935562›Full record

ArticleSaudi journal of biological sciences2021

Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies.

Qazi Mohammad Sajid Jamal, Varish Ahmad, Ali H Alharbi, Mohammad Azam Ansari, Mohammad A Alzohairy, Ahmad Almatroudi, Saad Alghamdi, Mohammad N Alomary, Sami AlYahya, Nashwa Talaat Shesha and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Saudi journal of biological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Qazi Mohammad Sajid JamalDepartment of Health Informatics, College of Public Health and Health Informatics, Qassim University, Al Bukayriyah, Saudi Arabia.
Varish AhmadHealth Information Technology Department, Faculty of Applied Studies, King Abdulaziz University, Jeddah, Saudi Arabia.
Ali H AlharbiDepartment of Health Informatics, College of Public Health and Health Informatics, Qassim University, Al Bukayriyah, Saudi Arabia.
Mohammad Azam AnsariDepartment of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia.
Mohammad A AlzohairyDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Qassim 51431, Saudi Arabia.
Ahmad AlmatroudiDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Qassim 51431, Saudi Arabia.
Saad AlghamdiLaboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Mohammad N AlomaryNational Centre for Biotechnology, King Abdulaziz City for Science and Technology (KACST), P.O. Box 6086, Riyadh 11442, Saudi Arabia.
Sami AlYahyaNational Centre for Biotechnology, King Abdulaziz City for Science and Technology (KACST), P.O. Box 6086, Riyadh 11442, Saudi Arabia.
Nashwa Talaat SheshaRegional Laboratory, Directorate of Health Affairs Makkah, Saudi Arabia.
Suriya RehmanDepartment of Epidemic Disease Research, Institute for Research and Medical Consultations (IRMC), Imam Abdulrahman Bin Faisal University, P.O. Box 1982, Dammam 31441, Saudi Arabia.
Qassim University · SAImam Abdulrahman Bin Faisal University · SAKing Abdulaziz City for Science and Technology · SAKing Abdulaziz University · SAUmm al-Qura University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human-to-human transmitted respiratory illness in COVID-19 affected by the pathogenic Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2), which appeared in the last of December 2019 in Wuhan, China, and rapidly spread in many countries. Thereon, based on the urgent need for therapeutic molecules, we conducted

Indexed as

Å, AngstromAntiviral drugsDoxorubicinExemestaneGatifloxacinHbond, Hydrogen bondkcal/mol, Kilocalories per molenm, nanometerns, nanosecondPandemicps, picosecondSARS-CoV-2Spike proteinuM, Micro Molar

Identifiers

PMID33935562
PMCPMC8079265
OpenAlexW3158629849

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.